SİPARİŞ TAKİP
-
Cerrahi Tıp Bilimleri
-
Dahili Tıp Bilimleri
İngilizce Kitaplar
- Cardiology
- Dermatology
- Emergency Medicine
- Endocrinology
- Epidemiology Statistics
- Family Medicine
- Forensic Medicine
- Gastroenterology
- Hematology & Immunology
- Infectious Disease
- Internal Medicine
- Nephrology
- Neurology
- Nuclear Medcine
- Oncology
- Pediatrics
- Pharmacology
- Physical Medicine & Rehabilitation
- Psychiatry & Psychology
- Public Health
- Pulmonary Medicine
- Radiology
Türkçe Kitaplar- Adli Tıp
- Aile Hekimliği
- Çocuk Sağlığı ve Hastalıkları
- Dermatoloji
- Endokrinoloji
- Enfeksiyon Hastalıkları
- Epidemiyoloji
- Fizik Tedavi & Rehabilitasyon
- Gastroenteroji
- Göğüs Hastalıkları
- Halk Sağlığı
- Hematoloji & İmmunoloji
- İç Hastalıkları
- Kardiyoloji
- Nefroloji
- Nükleer Tıp
- Onkoloji
- Psikiyatri & Psikoloji
- Radyoloji
-
Temel Tıp Bilimleri
- Beslenme
- Hemşirelik
- Veteriner Hekimlik
- Diş Hekimliği
- KAMPANYA
- ULUSLARARASI
Giriş Yap
Recent Advances in Hematology
- Yayınevi: Ankara Nobel Tıp Kitabevleri
- ISBN: 9786257146005
- Editör: Mehmet Sinan Dal
- Basım Yılı: 2020
- Baskı Sayısı: 1
- Sayfa Sayısı: 176
- Ebat: 16 x 24 cm
- Kapak / Cilt: Karton Kapak
- Dil: İngilizce
75 TL
Hafta içi 16:00 ve Cumartesi 14:00'a kadar verilen siparişler aynı gün içinde kargoya verilir.
Hematology includes a wide variety of diseases ranging from aggressive course leukemia and lymphomato asymptomatic diseases with benign character. Especially in the last 2 decades, a variety ofnew agents have been developed for the treatment of diseases in the field of hematology.
Scientists continue their studies on the use of targeted agents as much as they could instead of highdoseconventional chemotherapies in cancer treatment. Novel monoclonal antibodies, checkpointinhibitors, CAR-T or NK-T cell treatments and tumor vaccines are being investigated in the treatmentof many cancers. Despite these developments, no agent developed for hematological cancersin the last decade has been able to change the basic backbone treatment approaches. Many of themhave been approved for use as an adjunct to the main treatments or in the treatment of relapsedrefractory diseases. For example, although there are many new agents developed for the treatmentof multiple myeloma in the last decade, autologous stem cell transplantation remains the standardapproach in eligible patients.
